Summary
India is set to produce cheaper versions of a popular weight-loss drug as the patent on its key ingredient expires, allowing local pharmaceutical companies to compete. This change could significantly lower costs and increase access to these drugs in India and potentially other countries. Experts believe the demand for these drugs will grow rapidly, as they are already used widely to aid weight loss and manage diabetes.
Key Facts
- The patent for semaglutide, a key ingredient in popular weight-loss drugs, expires in India.
- The expiration will allow Indian companies to release cheaper generic versions.
- Analysts expect the semaglutide market in India could reach $1 billion.
- Prices for existing drugs like Ozempic and Wegovy are currently high, but are expected to drop significantly.
- Around 50 brands of semaglutide generics are expected to enter the market quickly.
- India’s pharmaceutical industry is currently valued at about $60 billion and is expected to double by 2030.
- Semaglutide is used for both diabetes and weight loss, affecting appetite and blood sugar.
- Lower-priced drugs could help many Indians, with over 77 million people living with type-2 diabetes.
